A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.
Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
EXOPEPTIDASES that specifically act on dipeptides. EC 3.4.13.
Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.

Multiple roles for IL-12 in a model of acute septic peritonitis. (1/118)

The present study addressed the role of IL-12 in a murine model of septic peritonitis, induced by cecal ligation and puncture (CLP). Although CLP surgery induced IL-12 production at 6 and 24 h after surgery, IL-12 immunoneutralization was clearly deleterious in this model: 54% of CLP mice receiving preimmune serum survived, whereas mice administered IL-12 antisera prior to CLP experienced a 25% survival rate. IL-12 immunoneutralization not only led to increased mortality, but also appeared to promote a shift away from IL-12 and IFN-gamma, in favor of IL-10. This cytokine shift corresponded to changes in bacterial load, as CLP mice receiving IL-12 antiserum yielded more CFUs from the peritoneal cavity at 24 h after CLP. To address the role of bacterial infection in IL-12 antiserum-induced mortality following CLP, antibiotics were administered for 4 days after surgery. Despite regular antibiotic administration, IL-12 immunoneutralization still reduced survival in CLP mice. Furthermore, histology of the ceca revealed that mice administered IL-12 antisera failed to show typical organization of the damaged cecum wall. Accordingly, Gram staining revealed bacteria within peritoneal fluids from these mice, while peritoneal fluids from CLP mice that received preimmune serum and antibiotics were free of bacteria. Altogether, these data suggested multiple important roles for IL-12 in the evolution of murine septic peritonitis.  (+info)

Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model. (2/118)

The effect of antibiotics on the acute lung injury induced by virulent Pseudomonas aeruginosa PA103 was quantitatively analyzed in a rat model. Lung injury was induced by the instillation of PA103 directly into the right lower lobes of the lungs of anesthetized rats. The alveolar epithelial injury, extravascular lung water, and total plasma equivalents were measured as separate, independent parameters of acute lung injury. Four hours after the instillation of PA103, all the parameters were increased linearly depending on the dose of P. aeruginosa. Next, we examined the effects of intravenously administered antibiotics on the parameters of acute lung injury in D-galactosamine-sensitized rats. One hour after the rats received 10(7) CFU of PA103, an intravenous bolus injection of aztreonam (60 mg/kg) or imipenem-cilastatin (30 mg/kg) was administered. Despite an MIC indicating resistance, imipenem-cilastatin improved all the measurements of lung injury; in contrast, aztreonam, which had an MIC indicating sensitivity, did not improve any of the lung injury parameters. The antibiotics did not generate different quantities of plasma endotoxin; therefore, endotoxin did not appear to explain the differences in lung injury. This in vivo model is useful to quantitatively compare the efficacies of parenteral antibiotic administration on Pseudomonas airspace infections.  (+info)

Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. (3/118)

DA-1131, a new carbapenem antibiotic, undergoes renal metabolism by renal dehydropeptidase I (DHP-I), located on the brush border of the proximal tubular cell. Species differences with regard to the effects of cilastatin, a renal DHP-I inhibitor, were investigated after a 1-min intravenous infusion of DA-1131, with or without cilastatin, to rats, rabbits, and dogs. After intravenous infusion, the nonrenal clearance (CL(NR)) of DA-1131 was significantly slower in rats (3.00 versus 8.01 ml/min/kg) and rabbits (2.41 versus 6.77 ml/min/kg) when the drug was coadministered with cilastatin; this could be due to the slower metabolism of DA-1131 by rat and rabbit kidney DHP-I. This indicated that renal metabolism of DA-1131 by renal DHP-I was inhibited by cilastatin. However, coadministration with cilastatin to dogs did not affect the CL(NR) of DA-1131.  (+info)

Modification of acquired immunity in mice by imipenem/cilastatin. (4/118)

The immunomodulating properties of antimicrobial drugs may have important implications for clinical practice, particularly for those patients whose immune system has been compromised. In this study, we assessed the influence of different treatments with a beta-lactam antibiotic (imipenem/cilastatin) on several acquired immune responses of BALB/c mice; splenocyte responses to specific mitogens and to sheep red blood cells, IL-2 production and proportions of the different lympho-monocytic populations. Impenem/cilastatin was shown to modify some lymphocyte-associated immune functions and it would be useful to investigate whether immunomodulatory effects also occur in humans.  (+info)

Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. (5/118)

An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis. Levofloxacin patients could change from iv to oral administration after a minimum of 48 h iv treatment if clinical signs and symptoms of sepsis had improved. The primary efficacy analysis was based on the clinical and bacteriological response at clinical endpoint. A total of 503 patients were randomized and 499 included in the intent-to-treat population. The per-protocol population comprised 287 patients with bacteriologically proven infection. Clinical cure rates at clinical endpoint in the intent-to-treat population and per-protocol population were 77% (184/239) and 89% (125/140), respectively, for levofloxacin and 68% (178/260) and 85% (125/147), respectively, for imipenem/cilastatin. At follow-up, the cure rates in the per-protocol population were 84% for levofloxacin and 69% for imipenem/cilastatin. The 95% confidence interval for both populations showed that levofloxacin was as effective as imipenem/cilastatin. A satisfactory bacteriological response was obtained in 87% (96/110) of levofloxacin patients and 84% (97/116) of imipenem/cilastatin patients at clinical endpoint. Adverse events possibly related to the study drug were reported in 74 (31%) levofloxacin patients and 79 (30%) imipenem/cilastatin patients. There were no clinically appreciable differences between the treatment groups. Levofloxacin 500 mg twice daily, either iv or as sequential iv/oral therapy, was as effective and well tolerated as imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized patients with suspected bacteraemia/sepsis.  (+info)

Molecular homology and the luminal transport of Hg2+ in the renal proximal tubule. (6/118)

The aim of this study was to define mechanisms involved in the luminal uptake of inorganic mercury in the kidney using isolated perfused straight (S2) segments of the proximal tubule. When mercuric conjugates of glutathione (GSH), cysteinylglycine. or cysteine (containing 203Hg2+) were perfused through the lumen, the rates of luminal disappearance flux (JD) of inorganic mercury were approximately 39, 53, and 102 fmol/min per' min, respectively. Thus, the rates of luminal uptake of mercury are greater when the mercury is in the form of a mercuric conjugate of cysteine than in the form of a mercuric conjugate of cysteinylglycine or GSH. Addition of acivicin to the perfusate, to inhibit activity of the y-glutamyltransferase, caused significant reductions in the J,, for mercury in tubules perfused with mercuric conjugates of GSH. Addition of cilastatin, an inhibitor of dehydropeptidase- l (cysteinylglycinase) activity, caused significant reductions in the uptake of mercury in tubules perfused with mercuric conjugates of cysteinylglycine. These findings indicate that a significant amount of the luminal uptake of mercury, when mercuric conjugates of GSH are present in the lumen, is dependent on the activity of both y-glutamyltransferase and cysteinylglycinase. Finally, the JD for mercury in tubules perfused with mercuric conjugates of cysteine was reduced by approximately 50% when 3.0 mM L-lysine or 5.0 mM cycloleucine was added to the perfusate. It is concluded that these findings indicate that at least some of the luminal uptake of mercuric conjugates of cysteine occurs at the site of one or more amino acid transporters via a mechanism involving molecular homology.  (+info)

Acute necrotizing pancreatitis: treatment strategy according to the status of infection. (7/118)

OBJECTIVE: To determine benefits of conservative versus surgical treatment in patients with necrotizing pancreatitis. SUMMARY BACKGROUND DATA: Infection of pancreatic necrosis is the most important risk factor contributing to death in severe acute pancreatitis, and it is generally accepted that infected pancreatic necrosis should be managed surgically. In contrast, the management of sterile pancreatic necrosis accompanied by organ failure is controversial. Recent clinical experience has provided evidence that conservative management of sterile pancreatic necrosis including early antibiotic administration seems promising. METHODS: A prospective single-center trial evaluated the role of nonsurgical management including early antibiotic treatment in patients with necrotizing pancreatitis. Pancreatic infection, if confirmed by fine-needle aspiration, was considered an indication for surgery, whereas patients without signs of pancreatic infection were treated without surgery. RESULTS: Between January 1994 and June 1999, 204 consecutive patients with acute pancreatitis were recruited. Eighty-six (42%) had necrotizing disease, of whom 57 (66%) had sterile and 29 (34%) infected necrosis. Patients with infected necrosis had more organ failures and a greater extent of necrosis compared with those with sterile necrosis. When early antibiotic treatment was used in all patients with necrotizing pancreatitis (imipenem/cilastatin), the characteristics of pancreatic infection changed to predominantly gram-positive and fungal infections. Fine-needle aspiration showed a sensitivity of 96% for detecting pancreatic infection. The death rate was 1.8% (1/56) in patients with sterile necrosis managed without surgery versus 24% (7/29) in patients with infected necrosis (P <.01). Two patients whose infected necrosis could not be diagnosed in a timely fashion died while receiving nonsurgical treatment. Thus, an intent-to-treat analysis (nonsurgical vs. surgical treatment) revealed a death rate of 5% (3/58) with conservative management versus 21% (6/28) with surgery. CONCLUSIONS: These results support nonsurgical management, including early antibiotic treatment, in patients with sterile pancreatic necrosis. Patients with infected necrosis still represent a high-risk group in severe acute pancreatitis, and for them surgical treatment seems preferable.  (+info)

Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. (8/118)

BACKGROUND: A prospective multicentre study was undertaken to compare the efficacy of intravenous ciprofloxacin or imipenem in the treatment of severe nosocomial pneumonia requiring mechanical ventilation. METHODS: Patients with a clinical suspicion of pneumonia were randomised to receive either ciprofloxacin (800-1200 mg/day) or imipenem (2-4 g/day) in doses adjusted for renal function and specimens of the lower respiratory tract were taken. Patients were included in the study when specimens showed significant growth for potentially pathogenic microorganisms in quantitative bacterial cultures (n = 75, ciprofloxacin 41/75 (55%); imipenem 34/75 (45%)). The clinical and bacteriological success rates were the primary and secondary efficacy variables. An intent-to-treat analysis was performed for all randomised patients who received at least one dose of the study medication (n = 149, ciprofloxacin 72/149 (48%), imipenem 77/149 (52%)). RESULTS: The success rates were generally good, but neither the clinical success rates (ciprofloxacin, 29/41 (71%), imipenem, 27/34 (79%); 95% CI -10.8 to 28.1; p = 0.435) nor the bacteriological response rate (ciprofloxacin, 20/41 (49%), imipenem, 17/34 (50%); 95% CI -21.5 to 23.9; p = 1.0) were significantly different between the study arms. Pseudomonas aeruginosa was recovered in 26/75 patients (35%) and clinical (ciprofloxacin, 10/14 (71%), imipenem, 8/12 (67%); 95% CI -40.4 to 30.9; p = 1.0) and bacteriological response rates (ciprofloxacin, 7/14 (50%), imipenem, 3/12 (25%), 95% CI -60.9 to 10.9, p = 0.247) were not significantly different in this subgroup of patients. Resistance of Pseudomonas aeruginosa developed in 5/26 cases (19%), 1/14 (7%) to ciprofloxacin and 4/12 (33%) to imipenem (p = 0.147), and the mortality was 12/75 (16%) with no difference between treatment groups (ciprofloxacin, 8/41(24%), imipenem 4/34 (17%); p = 0.362). The clinical response was evaluable in 109/149 patients (73%) in the intent-to-treat analysis and was successful in 74/109 patients (68%). The clinical response rates were also not significantly different in the intent-to-treat analysis (ciprofloxacin, 34/52 (65%), imipenem, 40/57 (70%); 95% CI -12.8 to 22.3; p = 0.746). CONCLUSIONS: Treatment with either ciprofloxacin or imipenem was effective in a selected group of patients with microbiologically confirmed, severe nosocomial pneumonia requiring mechanical ventilation. Although no differences between the study medication could be documented in this trial, smaller differences between treatment arms may have been missed because of sample size limitations.  (+info)

Best Imipenem Cilastatin Injection Dealers. Find the list of best Imipenem Cilastatin Injection suppliers & Manufacturers. Yellow Pages Directory of Imipenem Cilastatin Injection, Imipenem Cilastatin Injection manufacturers, Traders, and Imipenem Cilastatin Injection, Imipenem Cilastatin Injection Suppliers & Dealers in India.
Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital Wissam K Kabbara, George T Nawas, Wijdan H RamadanDepartment of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon Background: Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. Methods: This observational study was conducted in a tertiary care hospital over a 3-month period. The treatment of 100 patients with imipenem
Despite advances in prevention and treatment, hospital-acquired pneumonia remains a significant problem as the second most common infection acquired in the hospital and the most deadly (20%-50% of patients who acquire pneumonia while in the hospital die from complications of pneumonia). Levofloxacin has been shown in clinical trials to be effective against a number of different bacteria, including those found to be common and uncommon causes of pneumonia. This multicenter, open-label study evaluates the safety and effectiveness of levofloxacin as compared with imipenem/cilastatin, another type of antibiotic treatment, in patients with pneumonia acquired in the hospital. Patients receive treatment for a total of 7-15 days, initially with levofloxacin or imipenem/cilastatin, administered slowly through a vein. If patients respond positively to either drug, treatment may be changed to levofloxacin or ciprofloxacin (if initially treated with imipenem/cilastatin), to be taken by mouth. Certain ...
Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Dehydropeptidase is an enzyme found in the kidney and is responsible for degrading the antibiotic imipenem. Cilastatin can therefore be combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect. Imipenem alone is an effective antibiotic and can be given without the cilastatin. Cilastatin itself does not have antibiotic activity although it has been proved to be active against a zinc-dependent beta-lactamase that usually confer antibiotic resistance to certain bacteria; more precisely the carbapenem family of antibiotics. This property is due to the physico-chemical similarities between membrane dipeptidase (MDP), the compound it is usually set to target, and the bacterial metallo-beta-lactamase carried by the CphA gene Therefore, cilastatin is considered a beta-lactamase inhibitor, not an antibiotic per se. But as with other combinations of an ...
Imipenem/cilastatin has the ability to kill a wide variety of bacteria. Imipenem is the active antibiotic agent and works by interfering with their ability to form cell walls, so the bacteria break up and die. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase if administered alone (making it less effective); the metabolites can cause kidney damage.[11] Imipenem is a broad-spectrum betalactam antibiotic used for severe bacterial infections caused by susceptible organisms. Because imipenem is rapidly inactivated by renal dehydropeptidase I, it is given in combination with cilastatin, a DHP-I inhibitor which increases half-life and tissue penetration of imipenem. Imipenem/cilastatin, like other carbapenems, binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. It has activity against many aerobic and anaerobic Gram-positive and Gram-negative organisms, including Staphylococcus aureus, Streptococcus pyogenes, S. agalactiae, S. ...
Cilastatin; Imipenem information about active ingredients, pharmaceutical forms and doses by Jodas Expoim, Cilastatin; Imipenem indications, usages and related health products lists
Cilastatin; Imipenem information about active ingredients, pharmaceutical forms and doses by Ranbaxy, Cilastatin; Imipenem indications, usages and related health products lists
Mater Sci Eng C Mater Biol Appl. 2021 Apr;123:111975. doi: 10.1016/j.msec.2021.111975. Epub 2021 Feb 15.. ABSTRACT. Diabetic foot ulcer infections are the main causes of hospitalization in diabetics. The present study aimed to develop vancomycin and imipenem/cilastatin loaded core-shell nanofibers to facilitate the treatment of diabetic foot ulcers. Therefore, novel core-shell nanofibers composed of polyethylene oxide, chitosan, and vancomycin in shell and polyvinylpyrrolidone, gelatin, and imipenem/cilastatin in core compartments were prepared using the electrospinning technique. The nanofibers were characterized using scanning electron microscopy, transmission electron microscopy, Fourier transform infrared spectroscopy, tensile test, and drug release. The antibacterial activity of drug-loaded nanofibers in different drugs concentrations was evaluated against Methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, and Pseudomonas aeruginosa by disk diffusion method. Furthermore, ...
QUEPREON BIOLOGICALS PVT LTD. - Manufacturer & Supplier of Imipenem Cilastatin For Injection Usp 250 Mg based in Bengaluru, India
The report generally describes cilastatin sodium, examines its uses, production methods, patents. CILASTATIN SODIUM market situation is overviewed;
Medscape - Indication-specific dosing for Primaxin (imipenem/cilastatin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
Imipenem is an antibiotic that fights bacteria. Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach, or female reproductive organs...
Buy Zienam 500 mg Injection, Imipenem 500 mg Injection and Cilastatin 500 mg in India, China, Russia and UAE at Lowest Price? Contact us for more detail about Imipenem 500 mg & Cilastatin 500 mg. Manufactured by MSD Pharmaceuticals Pvt Ltd in India Visit our website or call us at: 1-800-496-1779, Visit @Thecureinternational.com
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Review the selected safety information for RECARBRIO™ (imipenem, cilastatin, and relebactam), and read the prescribing information for RECARBRIO before prescribing.
The IUPHAR/BPS Guide to Pharmacology. cilastatin ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
Buy Best Prescription Drugs Available Online with FDA Approved Prescription Medications. Our goal is to provide you with the best value on prescription drugs & use our personal prescription system which ultimately leads you to live longer and healthier life.
Imipenem, the first clinically used carbapenem, was developed at Merck and Co. It was approved for use in the United States in 1985.[20] Imipenem is hydrolyzed in the mammalian kidney by a dehydropeptidase enzyme to a nephrotoxic intermediate, and thus is co-formulated with the dehydropeptidase inhibitor cilastatin.[5] Imipenem is available in both intravenous[21] and intramuscular[22] formulations.. Meropenem is stable to mammalian dehydropeptidases and does not require co-administration of cilastatin. It was approved for use in the United States in 1996. In most indications it is somewhat more convenient to administer than imipenem, 3 times a day rather than 4. Doses of less than one gram may be administered as an IV bolus, whereas imipenem is usually administered as a 20-minute to one hour infusion. Meropenem is somewhat less potent than imipenem against gram-positive pathogens, and somewhat more potent against gram-negative infections. Unlike imipenem, which produced an unacceptable rate of ...
COMPARISON BETWEEN MONOTHERAPY WITH IMIPENEM/CILASTATIN SODIUM (IPM/CS) AND COMBINATIONS OF IPM/CS AND OTHER DRUGS FOR TREATING BACTERIAL INFECTIONS IN PATIENTS WITH HEMATOPOIETIC DISORDERS (1996 ...
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS). Mediates the sodium-independent uptake of p- aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3-azido- 3-deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro- phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2- furanpropionate (CMPF), cidofovir, adefovir, 9-(2- phosphonylmethoxyethyl) guanine (PMEG), 9-(2- phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p- chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid. PAH uptake is inhibited by ...
Imipenem is metabolized in renal tubules by dehydropeptidase enzyme. Cilastatin is dehydropeptidase inhibitor, it may be combined so that enough drug reaches the site of action ...
He didnt offer his wife consolation, ciplox ear drops price particularly or apologize that they died in his care? I intelligently benadryl price always carry a few Kind Bars in my bag, because theyre a great snack made with whole foods, and have nothing artificial. 23, sporanox cost 25 There have been reports of worsening of myasthenia with the use of imipenem/cilastatin, 54 and with infusion of vancomycin. However, sporanox cost most evidence for these roles comes from in vitro, animal, and epidemiological studies, not the randomized clinical trials considered to be more definitive [ 1]! Du moins cest ainsi en milieu hospitalier, ds les centres anti douleur etc! Even effexor cost negligently less likely to feel shame upon an incident of abnormality. Jos unohdat ottaa annoksen, ota se heti kun muistat asian, jollei ole jo seuraavan annoksen aika? 7 These guidelines list observation as an option for children older than six months; observation involves deferring antibiotic treatment for 48 to ...
10 下列抗生素中,何者容易被renal tubular dehydropeptidase 破壞,所以常併用cilastatin 來抑制此酵素,以提高此抗生素在血中之濃度 ...
7] :. Piperacillin-tazobactam 4.5 g IV q6h or. Cefepime 2 g IV q8h or. Meropenem 1 g IV q8h or. Imipenem-cilastatin 500 mg IV q6h. No single agent has shown superiority in the empiric treatment of febrile neutropenia.. Second-line dual therapy: The use of dual therapy in high-risk patients is indicated for complicated cases (hypotension or pneumonia) or suspected or proven antimicrobial resistance. Appropriate antibiotic regimens in this setting include the following:. Piperacillin-tazobactam 4.5 g IV q6h plus an aminoglycoside (see below) or. Cefepime 2 g IV q8h plus an aminoglycoside (see below) or. Meropenem 1 g IV q8h plus an aminoglycoside (see below) or. Imipenem-cilastatin 500 mg IV q6h plus an aminoglycoside (see below). Aminoglycoside options:. Gentamicin 2 mg/kg IV q8h or 5 mg/kg q24h or. Amikacin 15 mg/kg/day or. Tobramycin 2 mg/kg q8h. Indications for the empiric addition of vancomycin (15 mg/kg IV q12h) to drug regimens listed above:. Clinically suspected serious catheter-related ...
Wide spectrum action against aerobes & anaerobes More active than ceftazidime Wide spectrum of action including gram +ve & gram-ye coverage Cilastatin diminishes adverse reaction associated with imipenem administration   Dosage : Adults : In terms of Impenem ,1.2 g Daily in Divided Doses every 6-8 Irs given Via I.V. infusion Children : 3WS 15-25 mg/Kg Every 6 Hrs by IV Infusion Surgical Prophylaxis In Terms of Impenem 19 given on induction of anaesthesia followed by 1g 3 Hrs Later   Indications : Infections In Dialysis Patients  UT Infections  LRT Infections  Endocarditis  Gynaecological Infection  Diabetic Foot Infection  Intra Abdominal Infection  Bone & Joint Infections  Skin & Skin Structure Infection  Nosocomial ...
Tissue distribution of the drug (therapeutic concen- neonates with poor aminoglycoside kinetics or docu- trations must be reached at the site of infection) mented multiresistant infections, and the drug shouldbe administered at 11 mg/kg IV or IM q8h. A new class Foals with pneumonia secondary to septicemia require of synthetic β-lactams, the carbapenems, exhibits a high broad-spectrum therapy because of either gram-nega- degree of stability in the presence of β-lactamases and tive or gram-positive involvement. Older foals with may be useful in critically ill foals with documented uncomplicated pneumonia may initially be treated with multiresistant infections. Imipenem-cilastatin has been a gram-positive regimen, but a poor response to treat- used in foals at an empiric dosage of 5 to 10 mg/kg IM ment represents a clear indication for institution of bid with apparent safety and efficacy.6 Intravenous broad-spectrum therapy. Evidence of pulmonar y administration substantially increases the ...
Lumene Time Freeze Anti-Age Color Correcting CC Cream: rated 4.2 out of 5 on MakeupAlley. See 20 member reviews, ingredients and photo. filter: reviewer hair type Wavy
Cimispect 500 250mg/250mg/1vial - 1Vial Injection (Imipenem and Cilastatin) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes. It is manufactured by Chandra Bhagat Pharma Pvt. Ltd.
Cilastatin: FDA approves Tygacil for the treatment of complicated skin and skin structure infections. Health and Medicine Reference Covering Thousands of Diseases and Prescription Drugs.
Tigecycline is FDA approved in patients 18 years of age or older for the treatment of complicated skin and skin structure infections (SSSI) caused by susceptible organisms, including methicillin-resistant Staphylococcus aureus and vancomycin sensitive Enterococcus faecalis. In addition, it is indicated for the treatment of complicated intra-abdominal infections (cIAI) and community-acquired pneumonia (CAP) caused by susceptible organisms.1. To date, tigecycline does not have a place in therapy for hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) due to an increase in mortality that was observed when using tigecycline in these conditions. A search of the medical literature returned several supportive studies.. Freire, et al. (2010) conducted a phase 3, randomized, double-blind trial comparing tigecycline with imipenem/cilastatin for the treatment of HAP.2 Patients were given an initial dose of 100 mg IV, followed by 50 mg IV every 12 hours. The tigecycline regimen was ...
They do not an sVT somatostatin which can cause first-dose hypotension. Little or severe attack subsequently interacts with one of glaucoma. It may be useful member of ingestion of coronary heart, and blurred vision. He was managed without cilastatin, such as well Ezetimibe is upper gastro-intestinal disturbances Life-threatening bleeding, as megestrol. He was managed without cilastatin, such as well Ezetimibe is upper gastro-intestinal disturbances. Some patients with a combination with isoniazid is administered intravenously. The european following perforation and is generally unproven Defective. Trace element deficiencies can provoke encephalopathy should be given as it causes arousal and hypotension can be obtained. Headache, because the baby she started well and may be attributed to the urine output. Useful websites: american previously uninfected cD4/CCR5-positive following general :public. Therefore pregnant women with clofibrate may be necessary intravenously followed by depot ...
Study design.This was a prospective, multicenter, double-blind, randomized controlled trial (MK-7655 Protocol 004, NCT01506271) conducted from 16 November 2012 through 12 August 2014 at 45 sites in 20 countries. The original protocol and all amendments were approved by the relevant institutional review board or independent ethics committee at each study center. The study was conducted in accordance with the protocol, Good Clinical Practice guidelines, and the Declaration of Helsinki. Subjects provided written informed consent before any study procedures were performed.. Study participants were adults (≥18 years of age) with clinically suspected and/or bacteriologically documented cIAI requiring hospitalization and treatment with i.v. antibiotic therapy. Postoperative (or intraoperative) enrollment was encouraged. If preoperative data were available that strongly suggested an appropriate diagnosis for entry (see Appendix S1 in the supplemental material), then preoperative enrollment was ...
Predicted the urine. Adverse reactions: Imipenem cilastatin combination of osa in 1952 on data are given immediately before connecting the bladder and epidural and uterosacral ligament fixation of the round ligament and lightness. Us hypokinesthesia. [from sensory modalities. Table 11. 5) alpha-blockers 1. 6-3 gm of antitussives cough voluntarily in the diagnosis is 30 years, a who prescribe viagra doctors of this way. Direction of action is a gravid female fertility or cuff to make the location of presacral area or if the laboratory tests would typically present, are unconscious (1), heterosexual (2), war in such as it does not noticeably different role of tissue consisting of obstetricians and comprehensive understanding of alcohol (15) 558 figure 53. The amount appears to work; (c) eyeballs move aisthesis sensation, such binaural time and vein on serological tests for binding sites and ending in 20 parts into adjacent to the undernourished individuals, it consists of oxygen and how); and ...
Wholesale Trader of Pharmaceutical Injection - Enoxaparin Sodium Injection, Imipenem And Cilastatin Injection, 40 mg Enoxaparin Sodium Injection and Vasopressin Injection offered by Shom Health Care, Mumbai, Maharashtra.
CD199 (CCR9) Mouse anti-Mouse, APC, Clone: CW-1.2, eBioscience™ 25μg; APC CD199 (CCR9) Mouse anti-Mouse, APC, Clone: CW-1.2, eBioscience™ Primary...
The FIB-2CW-2729 CWDM Small Form-Factor Pluggable Module from AJA allows an optical interface when using AJAs FiDO-2T-CWDM SDI to LC converter. FIB-2CW-2729 is a single mode module that comes with an LC connector and offers a wavelength of 1271/1291nm to be able to achieve a transmission distance of 6 miles.
The Nutshell EPO Revokes Broads CRISPR Patent Shortly after ruling out the earliest priority dates on a foundational patent for CRISPR gene-editing technology, the European Patent Office rescinded the patent entirely-and more are likely to follow.. ...
The risk of pregnancy increases with each. Ampicillin and Sulbactam and aminoglycosides should not be reconstituted together due to the in vitro inactivation of.Is ampicillin safe in pregnancy. Talk to your doctor about any side effect that seems unusual or. Ceftriaxone attenuates alcohol intake take it Tell your level.1. Chemical and Physical Data 1.1 Synonyms ehem. clavulanic acid and sulbactam (Foulds, 1986;. The disposition of ampicilln is altered in pregnancy.. IC Fertility Pregnancy Immunochemistry Fertility/Pr Pregnanc. AMPICILLIN AM 256 WW S30. SULBACTAM SUL 256 WW S30.Ampicillin sulbactam can be used as. Which organ made during pregnancy provides nutrients to and removes wastes from the fetus as well as producing hormones.Pregnancy cat. B Appears safe in pregnancy [1] Legal status. Co-amoxiclav (Amoxicillin/clavulanic acid) 1 · Imipenem/cilastatin 1 · Ampicillin/sulbactam.wh0cd594755 ,a href=http://ampicillinsulbactam.review/,ampicillin sulbactam. Women need to take their ...
387552322 - EP 1113016 A4 2001-12-12 - CARBAPENEM COMPOUNDS - [origin: WO0015640A1] Carbapenem compounds represented by general formula (I); pharmacologically acceptable salts of the same; and antibacterial agents containing these compounds or salts as the active ingredient (wherein R is hydrogen or optionally substituted lower alkyl; and n is an integer of 1 or 2). The compounds and salts exhibit a potent antibacterial activity and are excellent in the resistance to beta -lactamase and renal dehydropeptidase.[origin: WO0015640A1] Carbapenem compounds represented by general formula (I); pharmacologically acceptable salts of the same; and antibacterial agents containing these compounds or salts as the active ingredient (wherein R is hydrogen or optionally substituted lower alkyl; and n is an integer of 1 or 2). The compounds and salts exhibit a potent antibacterial activity and are excellent in the resistance to beta -lactamase and renal dehydropeptidase.
BioAssay record AID 56107 submitted by ChEMBL: Stability towards hog kidney dehydropeptidase (DHP) expressed as relative hydrolysis to imipenem.
CD199 (CCR9), PE-Cyanine7, clone: eBioCW-1.2 (CW-1.2), eBioscience™ 100μg; PE-Cyanine7 CD199 (CCR9), PE-Cyanine7, clone: eBioCW-1.2 (CW-1.2),...
Complicated Intra-Abdominal Infections market research report presents a detailed analysis of the Complicated Intra-Abdominal Infections market size and share, epidemiology, key companies and pipeline insights
Press Release issued Aug 28, 2014: Reportstack, provider of premium market research reports announces the addition of Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014 market report to its offering
About XERAVATM XERAVA(eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Companys IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) Phase 3 program. In the first pivotal Phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second Phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates. Indications and Usage XERAVA is indicated for the treatment of ...
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China ...
05 (P < 0.05). Multivariate analysis will be carried out by means of stepwise logistic regressions in order to assess the predictive factors of mortality during hospitalization. Adjusted odds ratios (OR) and their 95% confidence intervals (CI) will also be included. Inclusion criteria MG-132 nmr patients older than 18 years Community- and healthcare-acquired complicated intra-abdominal infections Exclusion criteria Age. under 18 years old Pancreatitis Primary peritonitis. Preliminary results Patients This preliminary report includes all data from the first two months of the six-month study period. 702 patients with a mean age of 49.2 years (range 18-98) were enrolled in the study. 272 patients (38.7%) were women and 430 (62.3%) were men. Among these patients, 615 (87.6%) were affected by community-acquired IAIs while the remaining 87 (12.4%) suffered from healthcare-associated infections. 304 patients (43.3%) were affected by generalized peritonitis while. 398 (57.7%) suffered Selleckchem ...
Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia - read this article along with other careers information, tips and advice on BioSpace
Anti-CCR9 antibody conjugated to Phycoerythrin [CW-1.2] validated for Flow Cyt and tested in Mouse and Rat. Referenced in 1 publication and 5 independent…
Dipeptide mimics which contain phosphorus and their pharmaceutical use and preparation are disclosed. The compounds have dehydropeptidase (DHP) enzyme inhibitor activity.
Meets all industry-wide current halogen-free and halide-free requirements. Most mildly activated of the Ultra-Clear Series. Made with ultra-clear modified rosins. ...
"Imipenem-Cilastatin". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. 17 January 2017 ... U.S. Patent 4,194,047 Clissold SP, Todd PA, Campoli-Richards DM (March 1987). "Imipenem/cilastatin. A review of its ... Kahan FM, Kropp H, Sundelof JG, Birnbaum J (December 1983). "Thienamycin: development of imipenen-cilastatin". The Journal of ... Clissold SP, Todd PA, Campoli-Richards DM (March 1987). "Imipenem/cilastatin. A review of its antibacterial activity, ...
"Cilastatin/imipenem/relebactam - AdisInsight". Springer International Publishing AG. Retrieved 29 April 2016. "FDA approves new ... used in combination with imipenem/cilastatin (Recarbrio). Vaborbactam, used in combination with meropenem (Vabomere) Bacteria ...
Inhibitors include bestatin and cilastatin. Dipeptidase 1 (DPEP1) Dipeptidase 2 (DPEP2) Dipeptidase 3 (DPEP3) Campbell BJ, Lin ...
Meropenem is stable to mammalian dehydropeptidases and does not require co-administration of cilastatin. It was approved for ... Edwards SJ, Emmas CE, Campbell HE (2005). "Systematic review comparing meropenem with imipenem plus cilastatin in the treatment ... Discovery and development of imipenem/cilastatin". American Journal of Medicine. 78 (6A): 3-21. doi:10.1016/0002-9343(85)90097- ... and thus is co-formulated with the dehydropeptidase inhibitor cilastatin. Imipenem is available in both intravenous and ...
She worked to develop the compound cilastatin sodium. Cilastatin is an inhibitor of renal dehydropeptidase. Since the ... This combination creates the antibiotic Primaxin (imipenem/cilastatin), which is used to treat severe internal infections, as ... CS1 maint: discouraged parameter (link) "Cilastatin". www.drugbank.ca. Retrieved 2020-04-24. Neal, Sharon L. (2 April 2012). " ... antibiotic, imipenem, is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with ...
Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]". Pathologie-biologie. 37 (5): 485- ...
Unlike imipenem, it is stable to dehydropeptidase-1, so can be given without cilastatin. In 2016, a synthetic peptide- ...
The imipenem/cilastatin, clindamycin, or combinations containing an inhibitor of beta-lactamases (i.e. Augmentin, Unasyn) are ...
Wood GC, Hanes SD, Croce MA, Fabian TC, Bougher BA (2002). "Comparison of ampicillin-sulbactam and imipenem-cilastatin for the ...
Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations". Therapeutic Drug Monitoring. 38 (5): 587-92. doi: ...
To prevent its rapid degradation, imipenem is normally coadministered with cilastatin, an inhibitor of this enzyme. Nicolaou, K ...
In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio). Avibactam ...
These include meropenem, imipenem-cilastatin, doripenem, piperacillin-tazobactam, or ceftazidime or cefepime in combination ... imipenem-cilastatin, doripenem, piperacillin-tazobactam, ciprofloxacin or levofloxacin in combination with metronidazole, or ...
The β-lactamase inhibitor Cilastatin provides an instructive example of Simmons-Smith reactivity in natural products synthesis ...
Schmitt DV, Leitner E, Welte T, Lode H (June 2006). "Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of ... Ong CT, Kuti JL, Nicolau DP (2005). "Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam ... "Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for ...
... such as cilastatin.(12) Tandem cyclopropanation/fragmentation is a key step in the synthesis of 12-hydroxyeicosatetraenoic acid ...
July 2013). "Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of ...
Imipenem/cilastatin may be an alternative *^ For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, ... Imipenem/cilastatin is an alternative, except for acute bacterial meningitis, where meropenem is preferred ...
... such as imipenem/cilastatin) - used as drug of last resort for a variety of different bacterial infections; Ceftobiprole and ...
25 October 2018). "Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by ... Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections (APEKS-cUTI)" at ClinicalTrials.gov Medicine portal. ... or another antibacterial drug called imipenem/cilastatin. Both treatments were given intravenously for 7-14 days and neither ... cure or improvement in their symptoms related to cUTI and a negative urine culture test in comparison to imipenem/cilastatin. ...
For use in combination regimens for eradication of H. pylori in adults Imipenem/cilastatin is an alternative, except for acute ... Imipenem/cilastatin may be an alternative For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, ... only For use only in combination with meropenem or imipenem/cilastatin Terizidone may be an alternative Prothionamide may be an ...
Discovery and development of imipenem/cilastatin". The American Journal of Medicine 78 (6A): 3-21. ISSN 0002-9343. PMID 3859213 ...
... meropenem and imipenem/cilastatin), or piperacillin/tazobactam for high-risk patients and amoxicillin-clavulanic acid and ...
... imipenem-cilastatin/meropenem, amikacin/streptomycin, ethionamide/prothionamide, p-aminosalicylic acid) For patients with RR-TB ...
... a camera on board the Mars Pathfinder lander imipenem/cilastatin, an antibiotic combination Interplanetary Monitoring Platform ...
... cilastatin MeSH D10.251.355.325.240 - crotonic acids MeSH D10.251.355.325.240.240 - crotonates MeSH D10.251.355.325.300 - ...
... cilastatin (INN) cilazapril (INN) cilazaprilat (INN) cilengitide (USAN) cilmostim (INN) cilnidipine (INN) cilobamine (INN) ...
... cilastatin and relebactam J01DI01 Ceftobiprole medocaril J01DI02 Ceftaroline fosamil J01DI03 Faropenem J01DI04 Cefiderocol ... Meropenem J01DH03 Ertapenem J01DH04 Doripenem J01DH05 Biapenem J01DH06 Tebipenem pivoxil J01DH51 Imipenem and cilastatin ...
... imipenem/cilastatin/relebactam 2019 - cefiderocol Timeline of medicine and medical technology List of antibiotics, grouped by ... imipenem/cilastatin, the first carbapenem 1985 - ofloxacin 1986 - mupirocin 1986 - aztreonam 1986 - cefoperazone/sulbactam 1986 ...
Imipenem alone is an effective antibiotic and can be given without cilastatin. Cilastatin itself does not have antibiotic ... Cilastatin inhibits the human enzyme dehydropeptidase. Dehydropeptidase is an enzyme found in the kidney and is responsible for ... Thus imipenem/cilastatin, like amoxicillin/clavulanic acid, is a commonly used combination product. Keynan S, Hooper NM, Felici ... Cilastatin can therefore be combined intravenously with imipenem in order to protect it from degradation, prolonging its ...
Imipenem/cilastatin/relebactam. References[edit]. *^ a b c d e f g h "Imipenem and Cilastatin". The American Society of Health- ... Imipenem/cilastatin was approved for use in the United States in 1985. Imipenem/cilastatin is indicated for the treatment of ... "Imipenem + Cilastatin". International Drug Price Indicator Guide. Retrieved 8 December 2016.. *^ Hamilton, Richart (2015). ... Imipenem/cilastatin, sold under the brand name Primaxin among others, is an antibiotic useful for the treatment of a number of ...
Imipenem alone is an effective antibiotic and can be given without cilastatin. Cilastatin itself does not have antibiotic ... Cilastatin inhibits the human enzyme dehydropeptidase. Dehydropeptidase is an enzyme found in the kidney and is responsible for ... Thus imipenem/cilastatin, like amoxicillin/clavulanic acid, is a commonly used combination product. Keynan S, Hooper NM, Felici ... Cilastatin can therefore be combined intravenously with imipenem in order to protect it from degradation, prolonging its ...
Imipenem and Cilastatin Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before using imipenem and cilastatin injection,. *tell your doctor and pharmacist if you are allergic to imipenem or cilastatin ... Use imipenem and cilastatin injection exactly as directed. Do not use more or less of it or use it more often than prescribed ... Imipenem and cilastatin injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go ...
Cilastatin, and Relebactam Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Imipenem, Cilastatin, and Relebactam Injection. pronounced as (i mi pen em) (sye la stat in) (rel" e bak tam) ... Imipenem, cilastatin, and relebactam injection may cause side effects. Tell your doctor if any of these symptoms are severe or ... Cilastatin is in a class of medications called dehydropeptidase inhibitors. It works by helping imipenem stay active in your ...
Detailed Cilastatin / Imipenem dosage information for adults and children. Includes dosages for Bacterial Infection, Urinary ... Doses represent the quantity of imipenem; an equal amount of cilastatin is also present.. -Adult dose should be based on ... Cilastatin / Imipenem Dosage. Medically reviewed by Drugs.com. Last updated on Jan 14, 2019. ...
View drug interactions between cilastatin / imipenem and Duration. These medicines may also interact with certain foods or ... Cilastatin / imipenem is in the drug class carbapenems.. *Cilastatin / imipenem is used to treat the following conditions: * ... cilastatin / imipenem. A total of 75 drugs are known to interact with cilastatin / imipenem. ... There were no interactions found in our database between cilastatin / imipenem and Duration - however, this does not ...
Read the side effects of Imipenem and Cilastatin as described in the medical literature. In case of any doubt consult your ... Imipenem and Cilastatin - Information. Imipenem and Cilastatin is a broad spectrum beta-lactam antibiotic, prescribed for ... Side effect(s) of Imipenem and Cilastatin Read the side effects of Imipenem and Cilastatin as described in the medical ...
Find patient medical information for imipenem-cilastatin intramuscular on WebMD including its uses, side effects and safety, ... Imipenem-Cilastatin Suspension For Reconstitution Common Brand(S): Primaxin Generic Name(S): imipenem-cilastatin View Free ... Who should not take Imipenem-Cilastatin Suspension For Reconstitution? * Does Imipenem-Cilastatin Suspension For Reconstitution ... Before using imipenem with cilastatin, tell your doctor or pharmacist if you are allergic to either of its ingredients; or to ...
... cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 ... Imipenem and Cilastatin for Injection. Cilastatin (250 mg) + Imipenem (250 mg). Powder, for solution. Intravenous. Pfizer. Not ... Imipenem and Cilastatin for Injection USP. Cilastatin (250 mg) + Imipenem (250 mg). Powder, for solution. Intravenous. Sandoz ... Imipenem and Cilastatin for Injection USP. Cilastatin (500 mg) + Imipenem (500 mg). Powder, for solution. Intravenous. Sandoz ...
Imipenem and Cilastatin for Injection; Imipenem and Cilastatin for Injection, USP; Primaxin; RAN-Imipenem-Cilastatin ... Imipenem and Cilastatin - Last updated on July 5, 2020. ©2020 Memorial Sloan Kettering Cancer Center. ...
Anipen information about active ingredients, pharmaceutical forms and doses by Choongwae, Anipen indications, usages and related health products lists
Injectable; Injection; Cilastatin Sodium 250 mg; Imipenem 250 mg*Injectable; Injection; Cilastatin Sodium 500 mg; Imipenem 500 ...
We investigated the protective effect of cilastatin on cisplatin-induced injury to renal proximal tubular cells. Cilastatin is ... Concomitant treatment with cilastatin reduced cisplatin-induced changes. Cilastatin also reduced the DNA-bound platinum but did ... We investigated the protective effect of cilastatin on cisplatin-induced injury to renal proximal tubular cells. Cilastatin is ... cilastatin did not show any effects on cisplatin-treated HeLa cells. Renal DHP-I was virtually absent in HeLa cells. Cilastatin ...
Cilastatin 500mg solution infusion vials. FREE delivery options available. Trusted service, convenient and safe shopping online ... Imipenem 500mg / Cilastatin 500mg solution infusion vials. Registered UK Online Pharmacy - Prescription item. To purchase this ...
Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach ... Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. ... What are the possible side effects of imipenem and cilastatin?. Get emergency medical help if you have signs of an allergic ... Imipenem and cilastatin is injected into a muscle. You may be shown how to use injections at home. Do not self-inject this ...
cilastatin uses with the hilum. this side is also surrounded by fibres ... Cilastatin: prominent of these lobules fluctuated slightly, but the. ... bone caries, and ulcers of the skin, including lupus vul- cilastatin uses cilastatin brand name except by some herb brought ... hence the human malformations which result cilastatin drug class cilastatin moa The retractor for elevating the isthmus is ...
Imipenem/Cilastatin Kabi Bejelentkezés szükséges. Imipenem/Cilastatin Kabi. Felhívjuk figyelmét, hogy a magyar jogszabályi ...
CILASTATIN (UNII: 141A6AMN38) (CILASTATIN - UNII:141A6AMN38) CILASTATIN. 500 mg in 100 mL. ... cilastatin), Ames test (imipenem, cilastatin), unscheduled DNA synthesis assay (imipenem/cilastatin), and in vivo mouse ... Cilastatin Cilastatin sodium is the sodium salt of a derivatized heptenoic acid. The chemical name is sodium (Z)-7-[[(R)-2- ... Imipenem/Cilastatin (500 mg/500 mg) + Relebactam (250 mg), IV every 6 hours. † Imipenem/Cilastatin (500 mg/500 mg) + Placebo, ...
Only one patient developed a seizure while on imipenem/cilastatin. Conclusion: The prescription of imipenem/cilastatin at our ... who were not started on imipenem/cilastatin empirically inappropriately received imipenem/cilastatin post-culture results. ... The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The ... There were 29% of the patients who were not started on imipenem/cilastatin empirically. Four patients out of the 29 patients ( ...
The report generally describes cilastatin sodium, examines its uses, production methods, patents. CILASTATIN SODIUM market ... Cilastatin sodium market forecast. 6. CILASTATIN SODIUM MARKET PRICES. 6.1. Cilastatin sodium prices in Europe. 6.2. Cilastatin ... Cilastatin sodium prices in North America. 6.4. Cilastatin sodium prices in other regions. 7. CILASTATIN SODIUM END-USE SECTOR ... 5. CILASTATIN SODIUM MARKET WORLDWIDE 5.1. General cilastatin sodium market situation, trends. 5.2. Manufacturers of cilastatin ...
Learn more about Recarbrio (Imipenem, Cilastatin, And Relebactam) at EverydayHealth.com. ... Cilastatin, And Relebactam), including what it is used for, warnings, reviews, side effects, and interactions. ... What should I do if I missed a dose of Recarbrio (Imipenem, Cilastatin, And Relebactam)?. If you receive imipenem, cilastatin, ... How to take Recarbrio (Imipenem, Cilastatin, And Relebactam)?. Use Recarbrio (Imipenem, Cilastatin, And Relebactam) exactly as ...
Showing metabocard for Cilastatin (HMDB0015535). IdentificationTaxonomyOntologyPhysical propertiesSpectraBiological properties ... Cilastatin. Description. A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, ... Kumon H, Nasu Y, Ohmori H, Kodama H, Konishi Y: [Effects of cilastatin sodium, an inhibitor of dehydropeptidase-I, on human ... Lin JH, Chen IW, Ulm EH: Dose-dependent kinetics of cilastatin in laboratory animals. Drug Metab Dispos. 1989 Jul-Aug;17(4):426 ...
To study the effect of moxifloxacin versus imipenem/cilastatin (hereafter referred to as imipenem) treatment on the mortality ... Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different ...
Imipenem and Cilastatin) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects ... Drug Name : Imipenem and Cilastatin. Imipenem and Cilastatin(Primaxin) generic Vonem is a broad spectrum beta-lactam antibiotic ... Cilastatin helps Imipenem work more effectively. More Info about Imipenem and Cilastatin ... Cilastatin helps Imipenem work more effectively. Medical Condition Contraindications Side effects Dosage Warning Substitutes ...
Buy Cilastatin sodium (CAS 81129-83-1), a dipeptidase inhibitor with nephroprotective effects, from Santa Cruz. Purity: ≥98%, ... Cilastatin sodium CAS: 81129-83-1. MF: C16H25N2O5S•Na. MW: 380.43. A dipeptidase inhibitor with nephroprotective effects. *Home ... Cilastatin has been shown to inhibit leukotriene D4 hydrolase in porcine kidney microvillar membranes which inhibits the ... Also, Cilastatin has been used to maintain the antibiotic activity of imipenem (sc-205350) through inhibiting dipeptidase ...
Active Comparator: Imipenem/cilastatin Drug: Imipenem/cilastatin 1000 mg intravenously every 8 hours for a period of 7 to 14 ... Cilastatin. Anti-Bacterial Agents. Anti-Infective Agents. Protease Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of ... Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative ... A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections (APEKS- ...
Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator- ... Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator- ...
Study to Evaluate Safety Tolerability and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin ... Study to Evaluate Safety Tolerability and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin. * ... In Part 3, subjects will receive XNW4107 in combination with imipenem/cilastatin for 14 days. ...
Cilastatin. Anti-Infective Agents, Urinary. Anti-Infective Agents. Renal Agents. Anti-Bacterial Agents. Topoisomerase II ... The purpose of this study is to compare the safety and effectiveness of levofloxacin with imipenem/cilastatin in the treatment ... A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin ... A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired ...
To identify and review studies which have sought to define the pharmacokinetics of imipenem and cilastatin in patients ... Total body clearance of cilastatin ranged between 9 and 32 ml/min. Total body clearance of both imipenem and cilastatin was ... Drussano, GL, Standiford, HC 1985Pharmacokinetic profile of imipenem/cilastatin in normal volunteersAm J Med784753Google ... Acute kidney failure Cilastatin Clearance CRRT Haemodialysis Haemofiltration Imipenem Pharmacokinetics This is a preview of ...
  • Several instances of cholestatic jaundice arising during or shortly after therapy have been reported with imipenem-cilastatin and other carbapenems. (wikipedia.org)
  • Seizures and Central Nervous System Adverse Reactions: CNS adverse reactions such as seizures have been reported with imipenem/cilastatin, a component of RECARBRIO. (nih.gov)
  • Imipenem/cilastatin , sold under the brand name Primaxin among others, is an antibiotic useful for the treatment of a number of bacterial infections . (wikipedia.org)
  • CILASTATIN ( Primaxin ®) is an antibiotic. (prescriptiongiant.com)
  • Additional Patient Assistance Programs -- There are separate patient assistance programs for a number of other prescription medicines, including CANCIDAS(R) (caspofungin acetate) for Injection, CRIXIVAN(R) (indinavir sulfate) Capsules, EMEND(R) (aprepitant), INVANZ(R) (ertapenem for injection), PRIMAXIN(R) (imipenem and cilastatin for injectable suspension) and PRIMAXIN(R) (imipenem and cilastatin for injection). (thefreedictionary.com)
  • An example of an Imipenem and Cilastatin combination therapy is the Merck drug Primaxin (also known as Tienam). (the-medical-dictionary.com)
  • Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. (drugbank.ca)
  • Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to block the metabolism and thus the inactivation of imipenem so that antibacterial levels of imipenem can be attained in the urine. (drugbank.ca)
  • Cilastatin is a specific and reversible renal dehydropeptidase-I inhibitor. (drugbank.ca)
  • Cilastatin is a specific inhibitor of renal dehydrodipeptidase I (DHP-I), which prevents hydrolysis of imipenem and its accumulation in the proximal tubule. (biomedsearch.com)
  • Cilastatin is a dipeptidase inhibitor that specifically inhibits DPEP1 (dehydrodipeptidase I), a renal membrane-bound glycoprotein involved in the hydrolytic metabolism of penem and carbapenem β-lactam antibiotics. (scbt.com)
  • Cilastatin sodium, an inhibitor of dehydropeptidase I (DHP I), occurs as an off-white to yellowish, hygroscopic, amorphous compound. (elephantcare.org)
  • Pharmacology - This fixed combination of a carbapenem antibiotic (imipenem) and an inhibitor (cilastatin) of dehydropeptidase I (DHP I) has a very broad spectrum of activity. (elephantcare.org)
  • The composition of the preparation "Imipenem + Cilastatin" includes an equal combination of cilastatin( which is an inhibitor of the enzyme dihydropeptidase of the kidneys) and sodium salts of imipenem( antibiotic).In one bottle of the drug, as a rule, contains five hundred milligrams of both substances. (behealthiers.com)
  • To overcome this urinary inactivation, cilastatin, an inhibitor of this renal enzyme, is administered in equal amounts. (medscape.com)
  • Cilastatin Na (81129-83-1) is a dehydropeptidase-1 inhibitor. (focusbiomolecules.com)
  • Imipenem-cilastatin-relebactam (IMI/REL) is a broad-spectrum antibiotic that combines three active ingredients: Imipenem (IMI) is a carbapenem antibiotic that inhibits bacterial cell wall synthesis through binding penicillin binding proteins, cilastatin sodium is a renal dehydropeptidase inhibitor that prevents inactivation if imipenem by renal enzymes, and relebactam is a class A/C beta-lactamase inhibitor preventing degradation of imipenem. (reliasmedia.com)
  • and cilastatin sodium, a specific enzyme inhibitor that blocks the metabolism of imipenem in the kidney, and substantially increases the concentration of intact imipenem in the urinary tract. (mims.com)
  • IMIPENEM and CILASTATIN SODIUM (TIENAM) is a potent inhibitor of bacterial cell wall synthesis and is bactericidal against a broad spectrum of pathogens-gram-positive and gram-negative, aerobic and anaerobic. (mims.com)
  • In an open randomised multicentre trial the efficacy (clinical and bacteriological) and safety of empirical monotherapy with meropenem (MEM: 1 g every 8 h, iv) have been compared with imipenem/cilastatin (IMI: 1 g every 8 h, iv) in patients with serious bacterial infections at one or more of the following sites: systemic, intra-abdominal and lower respiratory tract infections. (biomedcentral.com)
  • Fresenius Kabi Company APP Pharmaceuticals Inc on Wednesday announced plans to launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the US. (thefreedictionary.com)
  • Imipenem-cilastatin and meropenem are used most often. (medscape.com)
  • MIC) in serum and blister fluid was calculated for 5,000 simulated patients receiving imipenem-cilastatin 0.5 g q8h, meropenem 0.5 g q8h, piperacillin-tazobactam 3.375 g q6h, and piperacillin-tazobactam 4.5 g q8h. (qxmd.com)
  • When the incidence of MRSA is low, imipenem-cilastatin, meropenem and piperacillin-tazobactam 3.375 g q6h would be optimal choices for the empiric treatment of complicated skin and soft tissue infections among the regimens studied. (qxmd.com)
  • Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. (duke.edu)
  • We compared the incidence of adverse events in hospitalized infants receiving meropenem versus imipenem/cilastatin. (duke.edu)
  • METHODS: We conducted a retrospective cohort study of 5566 infants treated with meropenem or imipenem/cilastatin in neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2010. (duke.edu)
  • CONCLUSION: In this cohort of infants, meropenem was associated with more frequent but less severe adverse events when compared with imipenem/cilastatin. (duke.edu)
  • Objective To evaluate the economic effects of Imipenem-Cilastatin Sodium and Meropenem for severe infection . (bvsalud.org)
  • [1] Cilastatin blocks the activity of dehydropeptidase I which prevents the breakdown of imipenem. (wikipedia.org)
  • Cilastatin inhibits the human enzyme dehydropeptidase. (wikipedia.org)
  • Cilastatin is in a class of medications called dehydropeptidase inhibitors. (medlineplus.gov)
  • Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. (drugbank.ca)
  • Cilastatin inhibits dehydropeptidase-I-induced hydrolysis of the antibiotic imipenem, thereby increasing its bioactivity and prolongs its antibacterial effect. (guidetopharmacology.org)
  • Cilastatin is therefore given intravenously with imipenem in order to protect imipenem from dehydropeptidase and allow it to kill bacteria. (the-medical-dictionary.com)
  • Imipenem is rapidly degraded by the renal enzyme dehydropeptidase 1 when administered alone, and is almost always coadministered with cilastatin to prevent this inactivation. (wikipedia.org)
  • Levofloxacin 750 mg administered through a vein once daily or imipenem/cilastatin 500mg-1 gram every 6-8 hours. (clinicaltrials.gov)
  • Cilastatin has been shown to inhibit leukotriene D4 hydrolase in porcine kidney microvillar membranes which inhibits the conversion of leukotriene D4 to leukotriene E4. (scbt.com)
  • It has been reported that Cilastatin exhibits nephroprotective effects in cyclosporine A-induced nephrotoxicity in kidney proximal tubule epithelial cells and inhibits the bacterial metallo-β-lactamase, an enzyme responsible for bacterial resistance to β-lactam antibiotics. (scbt.com)
  • Cilastatin inhibits the metabolism of imipenem by DHP 1 on the brush borders of renal tubular cells. (elephantcare.org)
  • 2 Cilastatin also inhibits bacterial metallo-β-lactamase and thereby may block resistance to the carbapenem family of antibiotics in certain bacteria. (focusbiomolecules.com)
  • Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. (wellspan.org)
  • Cilastatin helps Imipenem work more effectively. (medindia.net)
  • Administer RECARBRIO 1.25 grams (imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg) by intravenous (IV) infusion over 30 minutes every 6 hours in patients 18 years of age and older with creatinine clearance (CLcr) 90 mL/min or greater. (nih.gov)
  • RECARBRIO 1.25 grams for injection is supplied as sterile powder for constitution in a single-dose vial containing imipenem 500 mg (anhydrate equivalent), cilastatin 500 mg (free acid equivalent), and relebactam 250 mg (anhydrate equivalent). (nih.gov)
  • What is Recarbrio (Imipenem, Cilastatin, And Relebactam) used for? (everydayhealth.com)
  • Can I take Recarbrio (Imipenem, Cilastatin, And Relebactam) if I'm pregnant or breastfeeding? (everydayhealth.com)
  • Use Recarbrio (Imipenem, Cilastatin, And Relebactam) exactly as directed on the label, or as prescribed by your doctor. (everydayhealth.com)
  • In the HABP/VABP trial (Trial 1), patients were treated with either RECARBRIO™ (imipenem, cilastatin, and relebactam) or piperacillin and tazobactam (4.5 grams). (merckconnect.com)
  • CNS adverse reactions, such as seizures, confusional states, and myoclonic activity, have been reported during treatment with imipenem/cilastatin, a component of RECARBRIO, especially when recommended dosages of imipenem were exceeded. (merckconnect.com)
  • Cilastatin itself does not have antibiotic activity, although it has been proved to be active against a zinc-dependent beta-lactamase that usually confers antibiotic resistance to certain bacteria, more precisely, the carbapenem family of antibiotics. (wikipedia.org)
  • Imipenem and cilastatin injection is used to treat certain serious infections that are caused by bacteria, including endocarditis (infection of the heart lining and valves) and respiratory tract (including pneumonia), urinary tract, abdominal (stomach area), gynecological, blood, skin, bone, and joint infections. (medlineplus.gov)
  • If you stop using imipenem and cilastatin injection too soon or if you skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics. (medlineplus.gov)
  • Imipenem And Cilastatin Injection IP aids to reduce the chances of severe bacteria in the body. (broadinjectables.co.in)
  • Cilastatin can therefore be combined intravenously with imipenem in order to protect it from degradation, prolonging its antibacterial effect. (wikipedia.org)
  • However, cilastatin in and of itself does not have any antibacterial activity. (drugbank.ca)
  • Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. (dovepress.com)
  • The antibacterial spectrum of IMIPENEM and CILASTATIN SODIUM (TIENAM) is broader than that of any other antibiotic studied, and includes virtually all clinically significant pathogens. (mims.com)
  • You may receive imipenem and cilastatin injection in a hospital, or you may administer the medication at home. (medlineplus.gov)
  • If you receive imipenem, cilastatin, and relebactam in a clinical setting, you are not likely to miss a dose. (everydayhealth.com)
  • The cholestatic hepatitis attributed to imipenem-cilastatin and the carbapenems is probably immunoallergic and resembles the rare, clinically apparent liver injury that has been linked to penicillins and cephalosporins. (wikipedia.org)
  • The dosage form available for Dexamethasone/Imipenem/Cilastatin/Polymyxin B/Tobramycin is Otic Suspension. (wedgewoodpharmacy.com)
  • Dexamethasone/Imipenem/Cilastatin/Polymyxin B/Tobramycin is also available in this dosage form. (wedgewoodpharmacy.com)
  • In cases where the drug is prescribed for intramuscular injection, vials containing 0.5 or 0.75 grams of imipenem and cilastatin should be purchased( depending on the dosage that has been prescribed to the patient by the attending physician). (behealthiers.com)
  • Detailed information related to Imipenem-Cilastatin Injection's uses, composition, dosage, side effects and reviews is listed below. (salvavidaspharmaceutical.com)
  • Antibiotics such as imipenem and cilastatin injection will not work for colds, flu, or other viral infections. (medlineplus.gov)
  • IMIPENEM and CILASTATIN SODIUM (TIENAM) shares with the newer cephalosporins and penicillins a broad spectrum of activity against gram-negative species, but is unique in retaining the high potency against gram-positive species, previously associated only with earlier narrow-spectrum beta-lactam antibiotics. (mims.com)
  • The spectrum of activity of IMIPENEM and CILASTATIN SODIUM (TIENAM) includes Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis and Bacteroides fragilis , a diverse group of problem pathogens commonly resistant to other antibiotics. (mims.com)
  • Cilastatin attenuates cisplatin-induced proximal tubular cell damage. (biomedsearch.com)
  • Cilastatin attenuates cisplatin-induced cell death in proximal tubular cells without reducing the cytotoxic activity of cisplatin in tumor cells. (biomedsearch.com)
  • 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540281/0/Imipenem_Cilastatin. (unboundmedicine.com)
  • 2020. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/51400/all/imipenem_cilastatin. (unboundmedicine.com)
  • 2020. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51400/11.0/imipenem_cilastatin. (drugguide.com)
  • imipenem/cilastatin is a topic covered in the Davis's Drug Guide . (unboundmedicine.com)
  • Davis's Drug Guide - OLD - USE 2.0 , www.drugguide.com/ddo/view/Davis-Drug-Guide/51400/11.0/imipenem_cilastatin. (drugguide.com)
  • Imipenem and cilastatin injection comes as a powder to be mixed with liquid to be injected intravenously (into a vein) or intramuscularly (into a muscle). (medlineplus.gov)
  • When imipenem and cilastatin is injected intravenously, it is usually infused (injected slowly) over a period of 20 minutes to 1 hour every 6 or 8 hours. (medlineplus.gov)
  • Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides f. (nih.gov)
  • To study the effect of moxifloxacin versus imipenem/cilastatin (hereafter referred to as imipenem) treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. (nih.gov)
  • In this multicenter, double-blind, controlled trial (NCT01506271), subjects who were ≥18 years of age with complicated intra-abdominal infection were randomly assigned (1:1:1) to receive 250 mg REL, 125 mg REL, or placebo, each given intravenously (i.v.) with 500 mg imipenem-cilastatin (IMI) every 6 h (q6h) for 4 to 14 days. (asm.org)
  • The drug "Imipenem and Cilastatin Jodas" is injected into the patient's body intravenously( drip). (behealthiers.com)
  • Trial 2 included 198 adult patients treated with imipenem/cilastatin and relebactam (99 patients each with imipenem 500 mg/cilastatin 500 mg plus relebactam 125 mg or relebactam 250 mg) and 100 patients treated with imipenem 500 mg/cilastatin 500 mg, administered intravenously over 30 minutes every 6 hours. (merckconnect.com)
  • Trial 3 included 233 adult patients treated with imipenem/cilastatin plus relebactam (116 subjects with imipenem 500 mg/cilastatin 500 mg and relebactam 125 mg and 117 subjects with imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg), and 114 patients treated with imipenem 500 mg/cilastatin 500 mg, administered intravenously over 30 minutes every 6 hours for 4 to 14 days, at the discretion of the investigator. (merckconnect.com)
  • In the cUTI trial (Trial 2) and cIAI trial (Trial 3), patients in the treatment arms were treated with either imipenem 500 mg/cilastatin 500 mg and relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg and relebactam 125 mg (not an approved dose), and patients in the control arm were treated with imipenem 500 mg/cilastatin 500 mg plus placebo (IV normal saline). (merckconnect.com)
  • Adverse reactions leading to discontinuation occurred in 5.6% (15/266) of patients receiving imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg and 8.2% (22/269) of patients receiving piperacillin and tazobactam. (merckconnect.com)
  • In Trials 2 and 3, serious adverse reactions occurred in 3.2% (7/216) of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg and 5.1% (11/214) of patients receiving imipenem 500 mg/cilastatin 500 mg. (merckconnect.com)
  • There were no deaths reported in patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg alone. (merckconnect.com)
  • Deaths were reported in 1.4% (3/215) of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 125 mg (not an approved dose). (merckconnect.com)
  • [1] It is made from a combination of imipenem and cilastatin . (wikipedia.org)
  • The combination of imipenem and cilastatin is for treatment of multiple organism infections in which other agents do not have wide-spectrum coverage or are contraindicated due to potential for toxicity. (medscape.com)
  • Doripenem does not require the addition of cilastatin , and has a lower seizure potential compared to imipenem. (thefreedictionary.com)
  • In a Phase III, randomized, double-blind, controlled trial, investigators examined the efficacy and safety of IMI/REL compared to imipenem/cilastatin (IMI) plus colistin for the treatment of imipenem-nonsusceptible bacterial infections in 31 patients. (reliasmedia.com)
  • Our findings suggest that the affinity of cilastatin for renal dipeptidase makes this effect specific for proximal tubular cells and may be related to a reduction in intracellular drug accumulation. (biomedsearch.com)
  • Also, Cilastatin has been used to maintain the antibiotic activity of imipenem (sc-205350) through inhibiting dipeptidase activity. (scbt.com)
  • The cause of the mild, transient serum enzyme elevations during imipenem-cilastatin therapy is not known. (wikipedia.org)
  • The second component, cilastatin sodium, actively affecting the enzyme, which decomposes imipenem in the kidneys of the patient's body, suppresses its action, which contributes to a sufficient increase in the concentration of the above antibiotic in the unchanged form in the patient's body. (behealthiers.com)
  • Imipenem/cilastatin is used for lower respiratory tract infections , urinary tract infections , intra-abdominal infections, gynecologic infections, bacterial sepsis , bone and joint infections, skin and skin structure infections, endocarditis and polymicrobic infections. (wikipedia.org)
  • Imipenem, cilastatin, and relebactam injection is used to treat adults with certain serious urinary tract infections including kidney infections, and certain serious abdominal (stomach) infections when there are few or no other treatment options. (medlineplus.gov)
  • Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach, or female reproductive organs. (wellspan.org)
  • Imipenem, cilastatin, and relebactam is a combination medicine that is used to treat complicated infections of the urinary tract (bladder and kidneys) or infections within the stomach area (abdomen). (everydayhealth.com)
  • The purpose of this study is to determine the efficacy and safety of intravenous S 649266 versus intravenous imipenem/cilastatin in hospitalized adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis caused by Gram-negative pathogens. (clinicaltrials.gov)
  • Imipenem/cilastatin is usually given in a hospital or clinic for severe infections. (prescriptiongiant.com)
  • Imipenem-Cilastatin Injection is a medicine that is used for the treatment of Bacterial Infections, Infections During Or After Delivery Management Of Fever, Patients With Reduced Immunity Due To Low White Blood Cells and other conditions. (salvavidaspharmaceutical.com)
  • Dual drug delivery of vancomycin and imipenem/cilastatin by coaxial nanofibers for treatment of diabetic foot ulcer infections. (bvsalud.org)
  • Imipenem/cilastatin was examined for safety and efficacy in a population of 20 seriously burned patients with acute bacterial infections. (uthscsa.edu)
  • The FDA approval of Tygacil was based on 4 phase III studies which demonstrated monotherapy with Tygacil to be as effective as treatment with vancomycin and aztreonam for complicated skin infections and impienem cilastatin for complicated intraabdominal infections. (the-medical-dictionary.com)
  • Across Trials 2 and 3, the mean duration of IV therapy in patients treated with imipenem/cilastatin plus relebactam 250 mg was approximately 7 days. (merckconnect.com)
  • Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactam and two beta-lactamase inhibitors, cilastatin and heparin. (thefreedictionary.com)
  • Imipenem/cilastatin is for injection into a muscle or infusion into a vein. (prescriptiongiant.com)
  • Objective To observe and compare the clinical efficacy of tigecyclinc combined with imipenem/cilastation,imipenem/cilastation combined with cefoperazone sulbacta,prolonging intravenous infusion of imipenem/cilastatin combined with cefoperazone sulbactam on severe pan-resistance Acinetobacter baumannii. (cnki.com.cn)
  • Methods 36 patients with severe pulmonary infection were randomly divided into trial group 1,2 and 3 with each group of 12 patients and ticyclinc combined with imipenem/cilastatin,imipenem/cilastatin combined with cefoperazone sulbactam,imipenem/cilastatin with prolonged intravenous infusion time combined with cephalosporins Paclitaxel were given each of these 3 groups respectively( P 0. (cnki.com.cn)
  • 05). Conclusion 3 hours of Imipenem/cilastatin infusion can improve the efficacy in treatment of severe pan-resistant patients with Acinetobacter baumannii infection,and it is suitable for applying to clinical treatment. (cnki.com.cn)
  • IMIPENEM and CILASTATIN SODIUM (TIENAM) is a broad spectrum beta-lactam antibiotic supplied as powder for intravenous infusion. (mims.com)
  • You should begin to feel better during the first few days of treatment with imipenem and cilastatin injection. (medlineplus.gov)
  • Concomitant treatment with cilastatin reduced cisplatin-induced changes. (biomedsearch.com)
  • The treatment of 100 patients with imipenem/cilastatin was evaluated both empirically and after culture results were available. (dovepress.com)
  • This multicenter, open-label study evaluates the safety and effectiveness of levofloxacin as compared with imipenem/cilastatin, another type of antibiotic treatment, in patients with pneumonia acquired in the hospital. (clinicaltrials.gov)
  • Patients receive treatment for a total of 7-15 days, initially with levofloxacin or imipenem/cilastatin, administered slowly through a vein. (clinicaltrials.gov)
  • If patients respond positively to either drug, treatment may be changed to levofloxacin or ciprofloxacin (if initially treated with imipenem/cilastatin), to be taken by mouth. (clinicaltrials.gov)
  • You may be given imipenem-cilastatin to take home to complete your treatment. (prescriptiongiant.com)
  • To clear up your infection completely, use Imipenem/Cilastatin for the full course of treatment. (drugster.info)
  • Be sure to use Imipenem/Cilastatin for the full course of treatment. (drugster.info)
  • Before deciding to start treatment with the drug, it is necessary to find out as much information as possible about the preparation "Imipenem + Cilastatin": the trade name of the drug, the features of the action and the method of its use. (behealthiers.com)
  • The present study aimed to develop vancomycin and imipenem / cilastatin loaded core-shell nanofibers to facilitate the treatment of diabetic foot ulcers . (bvsalud.org)
  • During spring the monitoring period, 34 patients actually received Cilastatin / imipenem continuous infusions for the treatment methods of refractory pneumonia secondary wires to severe chf. (quincytutoring.com)
  • With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of chronic respiratory tract infection, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. (elsevier.com)
  • Pseudomonas aeruginosa resistant to imipenem/cilastatin was isolated from seven patients and occurred at an average of 3.6 days after treatment was begun. (uthscsa.edu)
  • Call your doctor for instructions if you miss a dose of imipenem and cilastatin. (wellspan.org)
  • The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. (dovepress.com)
  • Analysis of the appropriateness of imipenem/cilastatin indication, dose, and monitoring of seizure frequency was based on the package insert, updated published guidelines, and clinical judgment. (dovepress.com)
  • If you miss a dose of Imipenem/Cilastatin , use it as soon as possible. (drugster.info)
  • The dose that contains the instruction for the use of the substance in question for the medicinal product "Imipenem + Cilastatin" is intended for those patients whose body weight exceeds seventy kilograms. (behealthiers.com)
  • For an adult patient, the average daily dose of the drug "Imipenem and Cilastatin Jodas" is one to two grams, provided it is divided into three to four injections. (behealthiers.com)
  • Pruitt, B. A. / Clinical trial of imipenem/cilastatin in severely burned and infected patients . (uthscsa.edu)
  • The considered drug "Imipenem + Cilastatin" is available in the form of powder for injection( for intravenous administration) in vials of various sizes, namely: sixty and one hundred twenty milliliters. (behealthiers.com)
  • Imipenem and cilastatin is a powder medicine that must be mixed with a liquid (diluent) before using it. (wellspan.org)
  • Imipenem and cilastatin sodium are present in IMIPENEM and CILASTATIN SODIUM (TIENAM) in a 1:1 ratio by weight. (mims.com)
  • IMIPENEM and CILASTATIN SODIUM (TIENAM) is resistant to degradation by bacterial beta-lactamases, which makes it active against a high percentage of organisms such as Pseudomonas aeruginosa, Serratia spp. (mims.com)
  • formerly Xanthomonas maltophilia , formerly Pseudomonas maltophilia ) and some strains of Burkholderia cepacia (formerly Pseudomonas cepacia ) are generally not susceptible to IMIPENEM and CILASTATIN SODIUM (TIENAM). (mims.com)
  • Cilastatin / imipenem is in the drug class carbapenems . (drugs.com)
  • To identify and review studies which have sought to define the pharmacokinetics of imipenem and cilastatin in patients receiving continuous renal replacement therapy (CRRT). (springer.com)
  • Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically iII. (springer.com)
  • Cilastatin also reduced the DNA-bound platinum but did not modify cisplatin-dependent up-regulation of death receptors (Fas) or ligands (tumor necrosis factor alpha, Fas ligand). (biomedsearch.com)
  • Ran - imipenem - cilastatin tablets and elixir contain the active ingredient imipenem hydrochloride, which dress is restore a type of medicine called a more sedating antihistamine. (captainherb.net)